Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 5/2013

Open Access 01-11-2013 | Original Research

18F-fluoride Positron Emission Tomography Measurements of Regional Bone Formation in Hemodialysis Patients with Suspected Adynamic Bone Disease

Authors: Michelle L. Frost, Juliet E. Compston, David Goldsmith, Amelia E. Moore, Glen M. Blake, Musib Siddique, Linda Skingle, Ignac Fogelman

Published in: Calcified Tissue International | Issue 5/2013

Login to get access

Abstract

18F-fluoride positron emission tomography (18F-PET) allows the assessment of regional bone formation and could have a role in the diagnosis of adynamic bone disease (ABD) in patients with chronic kidney disease (CKD). The purpose of this study was to examine bone formation at multiple sites of the skeleton in hemodialysis patients (CKD5D) and assess the correlation with bone biopsy. Seven CKD5D patients with suspected ABD and 12 osteoporotic postmenopausal women underwent an 18F-PET scan, and bone plasma clearance, K i, was measured at ten skeletal regions of interest (ROI). Fifteen subjects had a transiliac bone biopsy following double tetracycline labeling. Two CKD5D patients had ABD confirmed by biopsy. There was significant heterogeneity in K i between skeletal sites, ranging from 0.008 at the forearm to 0.028 mL/min/mL at the spine in the CKD5D group. There were no significant differences in K i between the two study groups or between the two subjects with ABD and the other CKD5D subjects at any skeletal ROI. Five biopsies from the CKD5D patients had single tetracycline labels only, including the two with ABD. Using an imputed value of 0.3 μm/day for mineral apposition rate (MAR) for biopsies with single labels, no significant correlations were observed between lumbar spine K i corrected for BMAD (K i/BMAD) and bone formation rate (BFR/BS), or MAR. When biopsies with single labels were excluded, a significant correlation was observed between K i/BMAD and MAR (r = 0.81, p = 0.008) but not BFR/BS. Further studies are required to establish the sensitivity of 18F-PET as a diagnostic tool for identifying CKD patients with ABD.
Literature
1.
2.
Kiattisunthorn K, Moe SM (2012) Chronic kidney disease-mineral bone disorder: definitions and rationale for a systemic disorder. Clin Rev Bone Miner Metab 10:119–127CrossRef
3.
Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26:1368–1376 Erratum in J Bone Miner Res 2011;26:2793PubMedCrossRef
4.
Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL, Cauley JA, Jamal SA, Antoniucci DM, Cummings SR, Osteoporotic Fractures Research Group (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167:133–139PubMedCrossRef
5.
Taal MW, Roe S, Masud T, Green D, Porter C, Cassidy MJ (2003) Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 63:1116–1120PubMedCrossRef
6.
Brandenburg VM, Floege J (2008) Adynamic bone disease—bone and beyond. NDT Plus 3:135–147CrossRef
7.
Schwarz C, Sulzbacher I, Oberbauer R (2006) Diagnosis of renal osteodystrophy. Eur J Clin Invest 36(Suppl 2):13–22PubMedCrossRef
8.
Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH (1994) Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855–861PubMedCrossRef
9.
Rhee H, Song SH, Kwak IS, Lee SB, Lee DW, Seong EY, Kim IY (2012) Persistently low intact parathyroid hormone levels predict a progression of aortic arch calcification in incident hemodialysis patients. Clin Exp Nephrol 16:433–441PubMedCrossRef
10.
Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47:149–156PubMedCrossRef
11.
Goldsmith D, Kothawala P, Chalian A, Bernal M, Robbins S, Covic A (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. Am J Kidney Dis 53:1002–1013PubMedCrossRef
12.
Avram MM, Mittman N, Myint MM, Fein P (2001) Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38:1351–1357PubMedCrossRef
13.
Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X, Fouque D, ARNOS Study Investigators (2011) Association between very low PTH levels and poor survival rates in hemodialysis patients: results from the French ARNOS cohort. Nephron Clin Pract 118:c211–c216PubMedCrossRef
14.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130
15.
Miller PD (2008) The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 3:S140–S150PubMedCrossRef
16.
Ott SM (2008) Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol 3(Suppl 3):S151–S156PubMedCrossRef
17.
Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17PubMedCrossRef
18.
Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB (2011) Issues in modern bone histomorphometry. Bone 49:955–964PubMedCrossRef
19.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S22–S49
20.
Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ (2013) PTH—a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol 8:299–312PubMedCrossRef
21.
Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella D, Mazzaferro S, Napoletano I, Sardella D, Taggi F (1998) Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients. Nephrol Dial Transplant 13:2294–2302PubMedCrossRef
22.
Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G (2008) Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3–5. Clin Nephrol 70:296–305PubMedCrossRef
23.
Negrea LA (2012) Biochemical abnormalities in chronic kidney disease-mineral bone disease. Clin Rev Bone Miner Metab 10:149–162CrossRef
24.
Ureña P, De Vernejoul MC (1999) Circulating biochemical markers of bone remodelling in uremic patients. Kidney Int 55:2141–2156PubMedCrossRef
25.
Hawkins RA, Choi Y, Huang S-C, Hoh CK, Dahlbom M, Schiepers C, Satyamurthy N, Barrio JR, Phelps ME (1992) Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 33:633–642PubMed
26.
Messa C, Goodman WG, Hoh CK, Choi Y, Nissenson AR, Salusky IB, Phelps ME, Hawkins RA (1993) Bone metabolic activity measured with positron emission tomography and 18F-fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab 77:949–955PubMedCrossRef
27.
Piert M, Zittel TT, Becker GA, Jahn M, Stahlschmidt A, Maier G, Machulla HJ, Bares R (2001) Assessment of porcine bone metabolism by dynamic 18F-fluoride PET: correlation with bone histomorphometry. J Nucl Med 42:1091–1100PubMed
28.
Cook GJR, Blake GM, Marsden PK, Cronin B, Fogelman I (2002) Quantification of skeletal kinetic indices in Paget’s disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res 17:854–859PubMedCrossRef
29.
Frost ML, Fogelman I, Blake GM, Marsden PK, Fogelman I (2004) Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res 19:1797–1804PubMedCrossRef
30.
Frost ML, Blake GM, Cook GJ, Marsden PK, Fogelman I (2009) Differences in regional bone perfusion and turnover between lumbar spine and distal humerus: 18F-fluoride PET study of treatment-naive and treated postmenopausal women. Bone 45:942–948PubMedCrossRef
31.
Installe J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP, Lonneux M (2005) 18F-fluoride PET for monitoring therapeutic response in Paget’s disease of bone. J Nucl Med 46:1650–1658PubMed
32.
Piert M, Zittel TT, Jahn M, Stahlschmidt A, Becker GA, Machulla H-J (2003) Increased sensitivity in detection of a porcine high-turnover osteopenia after total gastrectomy by dynamic 18F-fluoride ion PET and quantitative CT. J Nucl Med 44:117–124PubMed
33.
Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, Verbruggen A, De Roo M (1997) Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 38:1970–1976PubMed
34.
Frost ML, Cook GJ, Blake GM, Marsden PK, Benatar NA, Fogelman I (2003) A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Miner Res 18:2215–2222PubMedCrossRef
35.
Frost ML, Siddique M, Blake GM, Moore AE, Schleyer PJ, Dunn JT, Somer EJ, Marsden PK, Eastell R, Fogelman I (2011) Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography. J Bone Miner Res 26:1002–1011PubMedCrossRef
36.
Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, Tsuchida T, Okazawa H, Fujibayashi Y, Baba H (2009) Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med 50:1808–1814PubMedCrossRef
37.
Frost ML, Moore AE, Siddique M, Blake GM, Laurent D, Borah B, Schramm U, Valentin M-A, Pellas TC, Marsden PK, Schleyer PJ, Fogelman I (2013) 18F-fluoride PET as a non-invasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: a prospective, randomized, controlled clinical study. J Bone Miner Res 28:1337–1347PubMedCrossRef
38.
World Health Organisation (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical support series 843. WHO, Geneva
39.
Siddique M, Frost ML, Blake GM, Moore AE, Al-Beyatti Y, Marsden PK, Schleyer PJ, Fogelman I (2011) The precision and sensitivity of 18F-fluoride PET for measuring regional bone metabolism: a comparison of quantification methods. J Nucl Med 52:1748–1755PubMedCrossRef
40.
Siddique M, Blake GM, Frost ML, Moore AE, Puri T, Marsden PK, Fogelman I (2012) Estimation of regional bone metabolism from whole-body 18F-fluoride PET static images. Eur J Nucl Med Mol Imaging 39:337–343PubMedCrossRef
41.
Blake GM, Siddique M, Puri T, Frost ML, Moore AE, Cook GJ, Fogelman I (2012) A semipopulation input function for quantifying static and dynamic 18F-fluoride PET scans. Nucl Med Commun 33:881–888PubMedCrossRef
42.
Siddique M, Frost ML, Moore AE, Fogelman I, Blake GM (2012) Whole body 18F-fluoride PET measurements of regional bone formation. Osteoporos Int 23(Suppl 5):S577
43.
Carter DR, Bouxsein ML, Marcus R (1992) New approaches for interpreting projected bone densitometry data. J Bone Miner Res 7:137–145PubMedCrossRef
44.
Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, Zoccali C, London GM, Vanholder R (2010) Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) chronic kidney disease-mineral and bone disorder (CKD-MBD) guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 25:3823–3831PubMedCrossRef
45.
Barreto FC, Barreto DV, Moysés RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB (2008) K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73:771–777PubMedCrossRef
46.
Carmen Sánchez M, Auxiliadora Bajo M, Selgas R, Mate A, Millán I, Eugenia Martínez M, López-Barea F (2000) Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 36:953–961PubMedCrossRef
47.
Torres A, Lorenzo V, Hernández D, Rodríguez JC, Concepción MT, Rodríguez AP, Hernández A, de Bonis E, Darias E, González-Posada JM et al (1995) Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47:1434–1442PubMedCrossRef
48.
Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y (1995) Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26(5):836–844PubMedCrossRef
49.
Yajima A, Inaba M, Tominaga Y, Tanaka M, Otsubo S, Nitta K, Ito A, Satoh S (2013) Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease. Ther Apher Dial 17(Suppl 1):41–48PubMedCrossRef
50.
Parfitt AM (2003) Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 12:387–403PubMedCrossRef
51.
Coen G (2005) Adynamic bone disease: an update and overview. J Nephrol 18:117–122PubMed
52.
Malluche HH, Mawad H, Monier-Faugere MC (2008) Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol 3(Suppl 3):S157–S163PubMedCrossRef
53.
Salusky IB, Goodman WG (2001) Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12:1978–1985PubMed
54.
Amerling R, Harbord NB, Pullman J, Feinfeld DA (2010) Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 29(3):293–299PubMedCrossRef
55.
Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6–16PubMedCrossRef
56.
Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA (2012) Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab 97(8):2799–2808PubMedCrossRef
57.
Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW, Denosumab Phase 3 Bone Histology Study Group (2010) Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25(10):2256–2265PubMedCrossRef
58.
Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley JA, Black DM, Delmas PD, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 24(3):389–397PubMedCrossRef
59.
Nishizawa Y, Inaba M, Ishii M, Yamashita H, Miki T, Goto H, Yamada S, Chaki O, Kurasawa K, Mochizuki Y (2008) Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J Bone Miner Metab 26(3):265–270PubMedCrossRef
Metadata
Title
18F-fluoride Positron Emission Tomography Measurements of Regional Bone Formation in Hemodialysis Patients with Suspected Adynamic Bone Disease
Authors
Michelle L. Frost
Juliet E. Compston
David Goldsmith
Amelia E. Moore
Glen M. Blake
Musib Siddique
Linda Skingle
Ignac Fogelman
Publication date
01-11-2013
Publisher
Springer US
Published in
Calcified Tissue International / Issue 5/2013
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-013-9778-7

Other articles of this Issue 5/2013

Calcified Tissue International 5/2013 Go to the issue

Original Research

Efficacy of Reversal of Aortic Calcification by Chelating Agents

Original Research

Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients

Original Research

Genetic Association Study of Dickkopf-1 and Sclerostin Genes with Paget Disease of Bone

Original Research

A 12-Year Ecological Study of Hip Fracture Rates among Older Taiwanese Adults

Original Research

The Long Bone Deformity of Osteogenesis Imperfecta III: Analysis of Structural Changes Carried Out with Scanning Electron Microscopic Morphometry

Original Research

Association Between Aortic Calcification and the Risk of Osteoporosis in a Chinese Cohort: The Chongqing Osteoporosis Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits